HuGE Literature Finder
Records
1
-
3
Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 Feb . Shi Yuankai, Zhao Yanqiu, Yang Sheng, Zhou Jianying, Zhang Liangming, Chen Gongyan, Fang Jian, Zhu Bo, Li Xingya, Shu Yongqian, Shi Jianhua, Zheng Rongsheng, Wang Donglin, Yu Huiqing, Huang Jianan, Zhuang Zhixiang, Wu Gang, Zhang Longzhen, Guo Zhongliang, Greco Michael, Li Xiao, Zhang |
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer chemotherapy and pharmacology 2018 May . Imai Hisao, Minemura Hiroyuki, Sugiyama Tomohide, Yamada Yutaka, Kaira Kyoichi, Kanazawa Kenya, Kasai Takashi, Kaburagi Takayuki, Minato Koichi, |
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: